Methotrexate Therapy Guidelines

Introduction to Methotrexate Therapy

Methotrexate is taken on a weekly schedule, with therapeutic benefits appearing in 3-12 weeks, and regular blood monitoring is essential, as recommended by the British Association of Dermatologists 1

Patients with risk factors for hepatotoxicity, including advanced age, alcohol consumption, hepatic dysfunction, and concomitant hepatotoxic medications, require more frequent monitoring, as suggested by the British Association of Dermatologists 1
Alcohol consumption should be limited during methotrexate therapy, as recommended by the British Association of Dermatologists 1
Clinical assessment should evaluate for side effects and risk factors at each visit, according to the Annals of the Rheumatic Diseases 2

Methotrexate is contraindicated in pregnancy and breastfeeding, and effective contraception is essential, as stated by the British Association of Dermatologists 1
Precautions are recommended in patients with liver dysfunction, alcohol consumption, advanced age, and potential drug interactions, as advised by the American Academy of Dermatology and the British Association of Dermatologists 1, 3

The recommended starting dose of methotrexate is 10-15 mg once weekly, with a gradual escalation to an optimal or maximum tolerable dose of 25-30 mg weekly, as supported by the Annals of the Rheumatic Diseases 2 and the American Academy of Dermatology 4
Starting doses of 12.5-20 mg/week have higher clinical efficacy compared to 5-10 mg/week, without increased toxicity, according to the 3e Initiative 2
Rapid dose escalation (5 mg/month) to 25-30 mg/week has higher efficacy compared to slow escalation (5 mg/3 months), though with slightly more adverse events, as reported in the Annals of the Rheumatic Diseases 2 and 5
The American College of Rheumatology and the British Association of Dermatologists recommend increasing the dose by 5 mg every month until reaching a dose of 25-30 mg weekly or the maximum tolerable dose 1, 5
Insufficient methotrexate dosing, starting with doses <15 mg weekly, may lead to inadequate response, according to the American College of Rheumatology 6, 7

At least 5 mg of folic acid per week is strongly recommended with methotrexate therapy, to reduce toxicity while maintaining efficacy, prevent folate deficiency, provide cardiovascular protection, and improve treatment continuation, as suggested by the Annals of the Rheumatic Diseases 2 and the American Academy of Dermatology 8, 1, 3, 4
Folic acid is preferred over folinic acid for routine supplementation due to its lower cost and similar efficacy, as recommended by the American Academy of Dermatology and rheumatology guidelines 3, 4, 2, 1
A minimum of 5 mg of folic acid per week is recommended, with up to 5 mg daily in patients with high doses of methotrexate or those experiencing side effects, as supported by the American Academy of Dermatology and the American College of Rheumatology 4, 2, 1, 7

Laboratory tests, including ALT/AST, creatinine, and complete blood count, should be performed every 1-1.5 months until a stable dose is reached, then every 1-3 months thereafter, as recommended by the Annals of the Rheumatic Diseases 2 and the American College of Rheumatology 2, 1
Regular monitoring of folate levels, homocysteine levels, complete blood count (CBC), liver function tests (ALT/AST), and renal function tests is essential, as advised by the American College of Rheumatology 2, 1
Liver toxicity requires stopping methotrexate if ALT/AST increases to greater than three times the upper limit of normal, with possible reinstitution at a lower dose after normalization, as advised by the Annals of the Rheumatic Diseases 2

Oral administration of methotrexate is the preferred initial route, as suggested by the American College of Rheumatology 6, 7
If there is an inadequate response or intolerance to oral methotrexate, consider split dosing or switching to subcutaneous administration, which has higher bioavailability and fewer GI side effects, as recommended by the American College of Rheumatology 6, 7 and the European League Against Rheumatism 5

Methotrexate is used as an alternative immunosuppressive agent in lupus nephritis when first-line agents cannot be used, according to the Kidney International guidelines 8
Switching to biologics is only indicated after failure of conventional DMARDs at optimal doses, as stated by the European League Against Rheumatism 5
Increasing the folic acid dose before considering switching to alternative DMARDs is recommended for patients experiencing methotrexate intolerance despite standard folic acid supplementation, as advised by the European League Against Rheumatism 7